Deucravacitinib

Short Description:

API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status
Deucravacitinib 1609392-27-9  041093  Nov.07, 2033 PV Completion

 

[Indication]

1. It is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

2. For the treatment of adults with active psoriatic arthritis.


Product Detail

Product Tags


  • Previous:
  • Next:

  • Write your message here and send it to us